Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

Private Equity Physician Roll-Ups: How the Model Works, Who Gets Paid and What Physicians Should Ask

A private equity physician roll-up buys a platform practice, adds smaller practices to it, runs the business side through a sponsor-owned management services organization (MSO) and sells the combined group several years later, often to another sponsor. Sellers get paid twice. They get cash at closing, and they get rollover equity that turns into cash only at that later sale. The sponsor earns the gap between the multiple it pays for small practices and the multiple the larger group sells for, plus earnings growth, minus debt. Before you sign anything, pin down three numbers: your multiple against the platform's, the platform's debt, and where your rollover sits in the equity waterfall. In the AMA's 2024 survey, 6.5 percent of physicians said their practice was PE-owned.

Who Gets Paid, and When

Party How it is paid When Ranking at exit
Lenders Interest and principal on platform debt Throughout the hold First, ahead of all equity
Sponsor fund Return on its equity At the platform sale or recapitalization Equal to you or ahead of you, depending on equity class
MSO Management fee charged to the physician PC Every month Paid out of practice revenue before physician compensation formulas
Platform management Salary plus incentive units Units pay at exit Incentive units dilute other holders
Selling physicians Cash at close, salary or production pay, rollover equity Cash at close, rollover at exit Rollover sits behind debt and any preferred equity
Sell-side advisers Transaction fees At closing Paid from deal proceeds

The rest of this page puts numbers on each row.

What the Data Shows About Who Owns Physician Practices

Six datasets support this page. Each measures a different population, so we do not add figures from one to another or compare them directly.

Source Population measured As of What it cannot tell you
AMA Physician Practice Characteristics in 2024 Surveyed U.S. physicians by practice ownership, compared with the 2012, 2020 and 2022 rounds 2024 survey Prices paid or buyer identity. PE ownership is self-reported
CMS National Health Expenditure fact sheet Total U.S. health spending by service and payer 2024 actuals, 2025 to 2034 projections Practice profitability or deal activity
PESP, Private Equity Healthcare Deals: 2025 in Review U.S. PE-backed healthcare deals in all subsectors, by deal type, built from PitchBook and LevinPro HC data. PESP is a watchdog group critical of PE Deals tracked in 2025 Deals it missed. PESP calls its count a likely underestimate
Bain & Company, Global Healthcare PE Report 2026 Global healthcare PE deal value and exits in all subsectors, including biopharma Full-year 2025 estimates. North America large-deal count as of November 2025 Physician deal counts or seller proceeds
FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks A sell-side bank's view of dermatology buyers and deal structures 2026 edition Verified closing prices or other specialties
SRS Acquiom 2026 earnout study Earnout use by U.S. PE buyers in deals SRS Acquiom tracks, all industries 2025 deals vs 2014 to 2022 Physician-specific earnout terms

Why sponsors want physician practices. The revenue base is large and growing. The CMS National Health Expenditure fact sheet reports that physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and CMS projects it will grow 5.5% a year on average over 2025 to 2034. That spending flows through practices that are mostly small and independently owned, which is the condition a roll-up needs.

Physician ownership is shrinking. The share of physicians in private practice, meaning a practice wholly owned by physicians, fell from 60.1 percent in 2012 to 42.2 percent in 2024, per the AMA. PE ownership is a small slice of that shift, and it is growing.

Physician practice ownership, AMA Physician Practice Characteristics in 2024 (surveyed U.S. physicians)

Measure Figure
Physicians in private practice, 2012 60.1%
Physicians in private practice, 2024 42.2%
Physicians in PE-owned practices, 2020 and 2022 About 4.5% in each round
Physicians in PE-owned practices, 2024 6.5%
Acquired in the past five years: PE-owned vs hospital-owned practices 38% vs 10.0%
Acquired before 2015: hospital-owned vs PE-owned practices 47.2% vs 17.1%
Private practice physicians in practices with fewer than 5 physicians 49.2%
Private practice physicians in practices with 50 or more physicians 11.8%

Source: AMA, Physician Practice Characteristics in 2024, 2024 survey.

Where US physicians worked in 2024, by practice ownership (% of physicians)
Private practice (physician-owned)42.2%Hospital-owned practice34.5%Directly employed by hospital12.2%Private equity-owned practice6.5%
Chart data
Private practice (physician-owned)42.2
Hospital-owned practice34.5
Directly employed by hospital12.2
Private equity-owned practice6.5

Source: American Medical Association, Physician Practice Benchmark Survey 2024

Three points matter for a seller.

The PE base is young. Thirty-eight percent of physicians in PE-owned practices were acquired in the past five years, per the AMA's 2024 survey. Many platforms have not yet completed the sale that turns rollover into cash. Get the sponsor's record on second exits before you put a value on its equity.

Independent practices are small. Almost half of private practice physicians (49.2 percent) work in groups of fewer than five. Only 11.8 percent are in groups of 50 or more. Most independent practices will be priced as add-ons, not platforms.

Specialty sets how many independent targets remain. The AMA reports private practice below half of physicians in most specialties in 2024, from 30.7 percent in cardiology to 46.9 percent in radiology, with three named exceptions.

Private practice share by specialty, 2024 (AMA press release on the 2024 Physician Practice Benchmark Survey)

Specialty Physicians in private practice What it means for a seller
Cardiology 30.7% Few independent targets left. Scarcity supports price
Radiology 46.9% Mid-range pool
Other surgical subspecialties 51.2% Larger pool. Buyers have alternatives
Orthopedic surgery 54% Larger pool. Buyers have alternatives
Ophthalmology 70.4% Largest pool. A buyer can walk to the next practice

An independent cardiologist belongs to a small remaining pool. An independent ophthalmologist is one of many. Fewer remaining targets give a seller more room on price and terms.

The Roll-Up Engine in 4 Moves

Move 1: buy the platform. The sponsor buys a group large enough to support a management team, a billing operation and a credit facility, and funds much of the price with debt. The cash flow of the practices it buys services that debt. If you roll equity, the debt is paid before your equity.

Move 2: add practices. Add-ons are how roll-ups grow. PESP tracked 1,029 PE-backed U.S. healthcare deals in 2025, across all healthcare subsectors: 151 leveraged buyouts, 664 add-on acquisitions and 214 growth investments, involving 420 platform companies and 708 investment firms.

Our arithmetic on PESP's 2025 counts (all inputs from the same PESP dataset, all healthcare subsectors)

Ratio Inputs Result
Add-ons per leveraged buyout 664 / 151 About 4.4
Add-ons as a share of all tracked deals 664 / 1,029 About 65%
Dental deals that were add-ons PESP's rounded 95% × 149 About 142

The first ratio compares two counts from the same year. It does not mean each 2025 buyout made 4.4 add-ons, since platforms bought in earlier years made many of the add-ons.

Dental is the clearest case of add-on-driven growth. PESP reports that 95 percent of its 149 tracked dental deals in 2025 were add-ons made by PE-owned platforms. PESP does not split general dentistry from orthodontics, oral surgery or other dental specialties.

Assume you are an add-on until the sponsor tells you otherwise. In the first meeting, ask two questions. Are you pricing my practice as a platform or as an add-on? At what multiple do you carry the platform today?

Private equity healthcare deals in 2025, by deal type (deals)
Add-on acquisitions664Growth investments214Leveraged buyouts151

PESP counts 1,029 deals in total and says the count is likely an underestimate.

Chart data
Add-on acquisitions664
Growth investments214
Leveraged buyouts151

Source: Private Equity Stakeholder Project, PE healthcare deals 2025 in review

Move 3: split clinical from non-clinical work through an MSO. The common structure is the "friendly PC." A professional corporation owned by one or more physicians holds the licenses, payer contracts and clinical staff. A platform-owned MSO provides billing, coding, HR, IT, purchasing and real estate under a long-term management agreement and charges a fee. The sponsor's economic interest sits in the MSO. Some states are tightening their rules on this model, so take questions about how it fits your practice to your own attorney, starting from our healthcare compliance due diligence guide. Our MSO guide explains how these agreements are built.

The commercial point for a seller is simple. Your income after closing depends on the MSO fee and on the PC's compensation formula, not on the headline price.

Move 4: sell or recapitalize the platform. After several years of add-ons, the sponsor sells the platform or brings in new investors through a recapitalization. Either event turns rollover equity into cash. This is the "second bite." The buyer is often another sponsor. The figures below are Bain's, and they cover all healthcare subsectors, not physician platforms alone.

Healthcare PE exit activity, 2025 (Bain & Company, Global Healthcare PE Report 2026)

Measure Population Figure
Sponsor-to-sponsor deals expected in 2025 Global, all healthcare More than 150, worth more than $120 billion, records for both
Deals above $1 billion North America, all healthcare 26 as of November 2025, against 14 in all of 2024
Share of those large deals that were sponsor-to-sponsor North America, all healthcare More than 70%
Expected exit value Global, all healthcare $156 billion in 2025, up from $54 billion in 2024

A sponsor-to-sponsor sale can require holders to roll part of their proceeds into the new owner's structure. That starts a new hold period with new debt. Ask in writing whether your operating agreement allows that and who decides. Our healthcare deal structures guide shows how rollover, earnouts and seller notes fit together.

What the Pitch Promises and How to Test It

Financial pressure starts many of these conversations. Medscape's 2025 Physician Compensation Report found about 40 percent of physicians seeking paid work outside their primary roles. Sponsors answer that pressure with three promises. A sale delivers none of them automatically.

Promise What to ask for Red flag
Better payer rates The platform's current commercial contracts in your state, and whether your practice moves onto them at closing or only at renewal. Rate gains apply to the commercial book. Medicare rates are set by CMS, and Medicare made up 21% of 2024 U.S. health spending against 31% for private insurance The platform has no other practices in your metro area, so it has no local density to negotiate with. Or your payer mix is mostly Medicare
Costly resources (EHR, revenue cycle, imaging, pathology, surgery centers) Which resources exist today, who paid for them and whether your MSO fee covers them Resources described as "planned," which you fund through lower pay before you see any benefit
Less administrative burden Staffing ratios and denial rates at practices acquired two or more years ago, plus two physician references you pick yourself The sponsor offers only references it chose

Multiple Arbitrage, With Worked Examples

Roll-up returns come from three sources: buying practices below the value of the combined group, growing earnings, and debt. The first is multiple arbitrage. A practice bought at a lower multiple is worth more the day it joins a platform valued at a higher one. Before the LOI, write down the multiple you are being paid and the multiple the sponsor uses for its platform. Then decide how much of that gap you want back through rollover.

Size decides how much of the gap you capture. FOCUS's 2026 dermatology benchmarks say platform-ready dermatology practices, typically $5 million or more of EBITDA, get the highest valuations and the most favorable structures, often 70 percent or more in cash at close plus meaningful rollover. Smaller practices get less. Contingent pay is rising too. In SRS Acquiom's 2026 study, U.S. PE buyers across all industries used earnouts in 24 percent of 2025 deals, up from 13 percent over 2014 to 2022. For practice-level pricing, see our healthcare valuation multiples guide.

Worked example 1: how pay normalization sets the price

Normalizing physician pay moves the EBITDA base more than any other adjustment. Owner physicians take most of their profit as distributions. A buyer that puts them on W-2 salaries adds payroll before any MSO fee, which reduces the EBITDA the multiple is applied to.

This is a hypothetical. All inputs are our assumptions and all results are our arithmetic, before taxes and fees.

Line Before sale After sale
Collections $6.0M $6.0M
Operating expenses, excluding physician pay $3.3M $3.3M
Physician pay (3 owners) $2.7M as distributions, $900K each $1.2M as salary, $400K each
Normalized EBITDA Not applicable. All profit goes to owners $1.5M
Price at about 6.7× Not applicable $10.0M total consideration (cash plus rollover), about $3.33M per owner

Each owner gives up $500K a year of income for about $3.33M of total consideration. Over a five-year employment term that is $2.5M of forgone pay per owner, undiscounted. The sale still creates about $0.83M per owner over those five years, plus any rollover upside, but most of the headline price is prepaid income. Sale proceeds and salary are taxed differently, which changes the trade, so have a tax adviser model the after-tax version for your own numbers.

Seller test: Ask for a pro forma P&L that shows your post-closing salary, the MSO fee and the practice EBITDA left after both. Compare it with what your practice actually kept in each of the last three years. If the pro forma works only because your pay goes down, the pay cut is part of the price.

Worked example 2: a $10 million sale with 20 percent rollover

This continues the hypothetical above. Every multiple, debt figure and growth figure is our assumption, chosen to show the mechanics, and all results are our arithmetic. None is a market quote.

Assumptions: EBITDA is as defined in the deal documents, after physician pay is normalized. The $10 million price is all fixed consideration, with no earnout. Cash figures are before taxes, fees and escrow. No new equity is issued during the hold in the base case. Rollover is illiquid until a sale or recapitalization. Exit values are undiscounted and assume the exit happens.

Base case: the platform sells at 12×. $10 million × 12 = $120 million of enterprise value. After $35 million of debt, equity is $85 million. Your 10 percent is $8.5 million, 4.25 times the $2 million you rolled.

Scenario Exit EBITDA Exit multiple Enterprise value Debt at exit Equity value Your 10% stake Multiple of $2M rolled
A. Growth plus multiple expansion $10M 12× $120M $35M $85M $8.5M 4.25×
B. Growth, exit flat at 9× $10M 9× $90M $35M $55M $5.5M 2.75×
C. Flat 9×, add-ons funded with $25M more debt $10M 9× $90M $60M $30M $3.0M 1.5×
D. Growth stalls, same heavy debt $7M 9× $63M $60M $3M $0.3M 0.15×

Where Scenario A's gain comes from: equity rose $65 million, from $20 million to $85 million. EBITDA growth valued at the entry multiple added $45 million ($5 million × 9). The move from 9× to 12× added $30 million ($10 million × 3). Net new debt took away $10 million. Your share of the multiple expansion alone is $3 million, about 35 percent of your $8.5 million payout. At a flat 9× (Scenario B), your stake is $5.5 million, $3 million less.

Same scenarios, four cap tables

Real cap tables are rarely as clean as the base case. Two added assumptions, both hypothetical:

Cap table case A B C D
1. Your 10%, one class of equity $8.5M $5.5M $3.0M $0.3M
2. Diluted to 8% by incentive units, one class $6.8M $4.4M $2.4M $0.24M
3. 10%, sponsor's $18M with a 1.0× participating preference $6.7M $3.7M $1.2M $0
4. Cases 2 and 3 combined: 8% of what remains after the $18M preference $5.36M $2.96M $0.96M $0

Case 3, Scenario A: $85 million minus the $18 million preference leaves $67 million, and 10 percent of that is $6.7 million. In Scenario D, the $3 million of equity is less than the preference, so the sponsor takes all of it. In Scenario A, the same headline deal pays you between $5.36 million and $8.5 million depending only on the equity terms.

These four cases simplify the waterfall. Real agreements add terms that move payouts further: preferred returns that accrue each year, hurdle values on incentive units, later capital calls and fees. Ask for the actual waterfall and run it yourself rather than relying on a summary.

A breakeven test for any offer. Your rollover returns its $2 million when your share of equity reaches $2 million. Our arithmetic, assuming $10 million of exit EBITDA:

Equity terms Debt at exit Equity needed Enterprise value needed Breakeven exit multiple
One class, 10% $35M $20M $55M 5.5×
One class, 10% $60M $20M $80M 8.0×
1.0× participating preference, 10% $35M $38M ($18M preference plus $20M to share) $73M 7.3×
1.0× participating preference, 10% $60M $38M $98M 9.8×

The closer breakeven sits to the 9× entry multiple, the more your rollover depends on the sponsor's timing and on market conditions rather than on your practice. In the last row, breakeven is above entry. You need multiple expansion just to get your money back.

Worked example 3: sponsor offer vs an all-cash bid

Rollover only pays if it beats the cash you gave up for it. Suppose a hospital or other buyer offers $9 million all cash for the same practice, against the sponsor's $8 million cash plus $2 million rollover. Assumptions, all ours: post-closing pay is the same under both offers, the platform exits in year 5, and you could otherwise earn 15 percent a year on the extra $1 million of cash.

Scenario Cap table cases that clear $2.01M Cases that fall short
A All four None
B All four None
C Cases 1 and 2 ($3.0M, $2.4M) Cases 3 and 4 ($1.2M, $0.96M)
D None All four

The sponsor offer wins when the platform grows and the equity terms are clean. It loses when debt piles up and a preference sits ahead of you. Get the sponsor's debt plan and full equity terms, then model your own numbers in the Deal Proceeds Calculator and the Rollover Equity Calculator.

When the Platform Underperforms

Sponsors spend the least time on Scenario D. Growth stalls, the platform carries the debt it took on for add-ons, and equity shrinks to a sliver. With a preference ahead of you, your rollover is worth nothing. Push Scenario D one step further, as our arithmetic: if EBITDA falls to $6 million at 9×, enterprise value is $54 million against $60 million of debt. Equity is zero, lenders are short $6 million and control of the platform can pass to them. In a restructuring, lenders sit ahead of every equity holder.

Your closing cash is already yours. Your obligations may outlast your equity. The employment agreement, the non-compete and the MSO agreement that binds your PC can stay in force after the equity is gone. Settle five points before you sign:

Question What a failed platform costs you
What happens to your employment agreement on a change of control or a lender takeover? A new owner may inherit your contract on its existing terms, including pay formulas it can change
Does the non-compete survive if the equity becomes worthless or the platform defaults? A restrictive covenant without a working employer can block you from practicing locally
Can the PC terminate the management agreement if the MSO stops performing? Without a termination right, the practice stays tied to a failing MSO
Who owns the patient records, phone numbers and payer contracts? These decide whether you can rebuild a practice quickly
Who pays for malpractice tail coverage if you leave? Tail coverage can be a large, unplanned cost at exit

Ask the sponsor directly whether any of its platforms has been restructured, sold below cost or wound down, and what physician holders received. Then verify the answer with physicians who held equity in those platforms, chosen by you.

Where Sponsors Were Active in 2025

PESP's 2025 counts give the subsector picture for U.S. PE-backed healthcare deals. Each count combines buyouts, add-ons and growth investments.

PE-backed U.S. healthcare deals by subsector, 2025 (PESP, PitchBook and LevinPro HC data, likely an undercount)

Subsector 2025 PE deals What a seller should check
Health IT 151 Whether the buyer is a software sponsor or a provider platform, and whether any earnout rides on revenue milestones
Dental care 149, of which 95% were add-ons How many platforms are buying in your metro area. Add-on pricing depends on competition among them
Outpatient care 148 Whether ancillary revenue such as imaging, lab and surgery center income stays with your practice or moves to the platform
Medtech 117 Whether the buyer is a roll-up or a product investor, since that changes the exit path
Behavioral health 56 Payer mix and how clinicians are staffed and paid after closing

PESP's top five does not break out dermatology. FOCUS Investment Banking's 2026 dermatology benchmarks count more than 35 sponsor-backed dermatology platforms operating nationally. With that many buyers, a dermatology seller should run a competitive process instead of answering the first inbound call.

The number of buyers in your specialty and region matters more to your position than any national deal count.

Regulatory Areas That Move Timing and Structure

Regulators are paying closer attention to PE-backed physician deals. Several states passed or expanded healthcare transaction laws aimed at PE firms and MSOs in 2025 and 2026, as summarized in Latham & Watkins' 2026 state regulatory review. These reviews matter to a seller for two reasons. They can push back the closing date, and your earnout and employment clocks move with it. They can also force the sponsor to change the structure, or end a deal that never closes.

Our guides to healthcare M&A process guide and to healthcare compliance due diligence guide outline the issues, and the questions they raise for your deal belong with your own attorney before you sign the LOI.

The commercial question for the sponsor is plain: which filings does this deal trigger, how much time do they add and who bears the cost of delay? Our healthcare M&A process guide covers the sequence.

Your Pre-LOI Preparation File: What to Assemble Before the Sponsor's Diligence Team Arrives

The sponsor will rebuild your financials its own way. If you build them first, you set the starting point for the EBITDA debate instead of reacting to the buyer's version. Every $100K of normalized EBITDA is worth about $0.67 million at this page's 6.7× add-on multiple and $0.9 million at the platform's 9×, so each line below is worth defending.

Item to assemble What to include Why it moves your price or terms
Three years of collections and operating expenses Monthly collections by payer, expenses by category, one-time costs flagged Worked example 1 starts from $6.0M of collections and $3.3M of expenses. Unflagged one-time costs come straight off your EBITDA
Owner pay history Distributions, salaries and benefits for each owner, by year The move from $900K to $400K per owner set the $1.5M EBITDA base. Know your own normalization before the buyer proposes one
Payer mix and commercial contracts Share of collections by payer, contract terms and renewal dates Promised rate gains apply only to the commercial book. A mostly Medicare practice should discount that promise
Ancillary revenue by line Imaging, lab, pathology and surgery center income, with the physicians who generate it Decides whether that income stays in your EBITDA or moves to the platform
Provider roster Age, production, contract end date and intent to stay for each clinician Earnouts and retention depend on who keeps producing after closing
Leases, equipment and debt Lease terms, equipment loans and lines of credit Sets what transfers, what is paid off at closing and what comes out of your $8M of cash
Referral concentration Share of new patients from your top ten sources Concentration lowers the multiple a buyer will pay and shapes how it structures contingent pay
Your own scenario model Scenarios A to D run with your figures and the sponsor's stated debt plan Lets you compare the sponsor offer with an all-cash bid on your terms, as in worked example 3

Ask your accountant to prepare the first three items as a quality-of-earnings-style summary. A seller who arrives with a clean file usually shortens diligence and leaves the buyer fewer reasons to reprice at closing.

Planning Your Closing Timeline: What a Delay Costs and What to Settle at Signing

A gap between signing and closing does not automatically cost you money. In this page's example, the owners keep running the practice at pre-sale pay until closing. The real risks are clocks that start on the wrong date, interim limits on how you run the practice, and a deal that falls apart after your staff and referral sources already know about it.

The delay math, using this page's figures (our arithmetic, before taxes, time value compounded annually at 15%):

Delay Time value lost on $8M closing cash Extra pay kept by the 3 owners ($2.7M distributions vs $1.2M salaries) Net to the owners
3 months About $0.28M $0.375M About +$0.09M
6 months About $0.58M $0.75M About +$0.17M
12 months $1.2M $1.5M About +$0.3M

The 15 percent rate comes from worked example 3 and the pay figures come from worked example 1. On these assumptions a delay roughly pays for itself, as long as the price holds, practice earnings hold and the deal closes. If collections dip while the deal is pending, or the buyer reprices at closing, that cushion disappears.

Terms to settle in the LOI, before any filing starts:

Term The reason What to ask for
Outside date Sets how long you are bound to a deal that has not closed A firm date, who can extend it and for how long
Who carries delay cost Decides whether a slip costs you or the buyer A price that holds through the outside date, or a ticking fee if closing slips
Interim operating limits Can stop you from hiring, signing payer contracts or buying equipment while you wait A short list of what needs buyer consent, plus a quick turnaround on requests
Earnout start date A measurement period that starts at signing can lose months to a pending review Measurement that starts at closing, with targets that shift if closing slips
Employment and non-compete start dates Decides whether time spent waiting counts against your term Both clocks starting at closing, not signing
Rollover valuation date Platform value can move while you wait Whether your rollover price is fixed at signing or reset at closing
A deal that fails Staff, referral sources and payers may already know about the sale Who pays which costs, a buyer non-solicit of your staff and a confidentiality plan

Before signing, build a one-page calendar showing signing, expected filing dates, the outside date, closing and the start of each clock. If the sponsor cannot fill it in, that tells you how prepared it is.

A Rollover Equity Checklist Before You Sign an LOI: 10 Questions and Why Each Changes Your Payout

The cap tables above show that structure, not headline price, decides what rollover pays. Labels like "pari passu" and "preferred return" mean little until you know who gets which dollar. Get written answers to these ten questions. Our Physician Rollover Equity Checklist has the full 25.

  1. Class and seniority. Is your rollover the same class as the sponsor's equity, or common behind preferred? In our example, a 1.0× participating preference cut Scenario A from $8.5 million to $6.7 million.
  2. Dilution. Will management incentive units, later add-on rollovers or new capital raises dilute you, and does new money come in with them? Incentive units that took you from 10 to 8 percent cut Scenario A by $1.7 million.
  3. EBITDA definition. Which adjustments go into the EBITDA used to price your practice and the platform? The same practice shows a different multiple on a different base.
  4. Cash, earnout and note mix. How much is paid at closing, how much rides on an earnout and how much comes as a seller note? Get the earnout metric, who controls it and how disputes are resolved.
  5. Exit control. Who decides when the platform is sold, and to whom? Look for tag-along rights, and for drag-along terms that force you to sell on the sponsor's terms. Ask whether you can be required to roll again if the buyer is another sponsor.
  6. Platform debt. Get current debt, borrowing capacity for add-ons and whether dividend recapitalizations are allowed. Debt is paid before equity, so it sets your breakeven exit multiple.
  7. Compensation after closing. Get the production formula, the share of collections that goes to the MSO and who can change either one.
  8. MSO fee terms. How is the fee calculated, who can raise it and what does it cover?
  9. Non-compete and timing. Confirm the radius and duration of the non-compete, and whether the clock starts at closing or when your employment ends. Get the sponsor's list of required filings and the time each adds.
  10. Sponsor equity and second-exit record. How much do the fund and its partners invest on the same terms you get? Which platforms has the sponsor already sold? How many physicians held equity in them, at what entry valuation, and what did the median physician holder receive?

Verify, do not just ask. Two free public tools help. Search the sponsor's fund names in SEC EDGAR full-text search for Form D notices, which show how much a fund has raised and when. If a banker or intermediary is bringing you the deal, look up the firm and the individual on FINRA BrokerCheck for registration and disclosure history. Our reverse due diligence guide covers the rest.

Alternatives to the Sponsor Model

Path What you get What you give up Best fit
PE platform (as add-on) Cash at close plus rollover, platform resources Control, some pay, liquidity on the rollover Practices that want a partial exit now and accept a second-bite bet
PE platform (as platform) FOCUS's best tier of valuation and structure in dermatology, a management role Control to the sponsor, debt on the platform Groups at $5 million or more of EBITDA
Hospital system Employment and a fixed price Rollover and any second bite Physicians who value certainty over upside
Family office Longer hold, flexible terms A defined exit date Practices a fund-clock platform would pass over
Merge with peers first Platform-level pricing later Time and integration work now Physicians in a fragmented specialty

Hospital systems. Hospital acquisitions of physician practices predate PE's. In the AMA's 2024 survey, 47.2 percent of physicians in hospital-owned practices said they were acquired before 2015, against 17.1 percent in PE-owned practices. A hospital offers employment and a fixed price, with no rollover and no second bite. Get a hospital bid before you sign an exclusive LOI with a sponsor, if only to set a floor. Worked example 3 shows how to compare the two.

Family offices. A family office has no fund clock, so it can hold a practice that a platform would pass over. Ask how long it plans to hold, whether a later sale is planned and how terms change if you become unable to practice. Our guide to how family offices invest in healthcare covers their structures.

Becoming the platform. In FOCUS's 2026 dermatology benchmarks, groups at $5 million or more of EBITDA sit in the platform-ready tier with the best valuations and structures. Physicians in a fragmented specialty can merge with peers before selling instead of selling one practice at a time. Smaller buy-ins can be financed through the SBA 7(a) loan program, the SBA's main small business loan program.

For the sale process itself, read our guide to selling a physician practice.

Questions Practice Owners and Investors Ask

What percentage of physicians work in private equity-owned practices?

In the AMA's Physician Practice Characteristics in 2024 report, 6.5 percent of surveyed physicians said their practice was private equity-owned. The share was about 4.5 percent in both the 2020 and 2022 survey rounds. Most PE ownership is recent. Thirty-eight percent of physicians in PE-owned practices said they had been acquired in the past five years, against 10.0 percent of physicians in hospital-owned practices. These are self-reported shares of physicians, not deal counts.

How much of the purchase price do physicians receive in cash at closing?

It depends on size. FOCUS Investment Banking's 2026 dermatology benchmarks say platform-ready practices, typically $5 million or more of EBITDA, get the most favorable structures, often 70 percent or more in cash at close plus meaningful rollover equity. Smaller add-ons get less favorable terms. Contingent pay is also more common. In SRS Acquiom's 2026 earnout study, U.S. private equity buyers across all industries used earnouts in 24 percent of 2025 deals, up from 13 percent over 2014 to 2022. Rollover equity turns into cash only when the platform is sold or recapitalized.

Are private equity physician roll-ups slowing down?

Not on 2025 data. The Private Equity Stakeholder Project tracked 1,029 PE-backed U.S. healthcare deals in 2025 across all subsectors, 664 of them add-on acquisitions, using PitchBook and LevinPro HC data, and calls its count a likely underestimate. Bain & Company's global figures point the same way. Bain estimates global healthcare PE deal value reached a record $191 billion in 2025 and expected exit value of $156 billion, up from $54 billion in 2024. Bain's figures cover every healthcare subsector worldwide, including biopharma, so they show market direction, not physician deal counts.

What is the second bite of the apple in a physician roll-up?

It is the payout on rollover equity when the platform is sold or recapitalized, usually several years after the first closing. The buyer is often another sponsor. Bain's 2026 report expected more than 150 global healthcare sponsor-to-sponsor deals in 2025, worth more than $120 billion, across all healthcare subsectors. What a physician receives depends on platform debt, the exit multiple and the equity terms. In the illustrative example on this page, the same $2 million rollover pays between $0 and $8.5 million depending on those three variables.

Sources